GH ADMINISTRATION ON CARDIOVASCULAR RISK IN SUBJECTS W/GROWTH HORMONE DEFICENCY

GH 给药对生长激素缺乏症患者心血管风险的影响

• 批准号: 7374766
• 负责人: ANNE KLIBANSKI
• 金额: $ 0.41万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374766
• 关键词: GH; ADMINISTRATION; CARDIOVASCULAR; RISK; SUBJECTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. With the accumulation of evidence on the beneficial effects of GH replacement, this therapy is becoming standard of care in all subjects with GH deficiency (GHD), except in this acromegaly subgroup where GH has been traditionally withheld. The GHD syndrome is manifested by an increase in cardiovascular risk, which is potentially reversible with GH therapy. Cardiovascular disease is the leading cause of death in acromegalics. Although cure of acromegaly is associated with a reduction in mortality attributable to GH excess, GHD may be a contributing factor to cardiovascular morbidity and mortality in this group of patients, as it is in patients with other pituitary tumors. The aim of the study is to evaluate the effects of physiologic growth hormone (GH) replacement on cardiovascular risk markers, cardiac autonomic function, arterial distensibility, body composition, and quality of life in men and women with GH deficiency following treatment of acromegaly. We will compare GH sufficient with GH deficient cured acromegalics in a cross-sectional study. We hypothesize that this population will represent a newly identified group of patients for whom GH replacement will be of benefit.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。随着GH替代治疗有益作用证据的积累，该疗法正成为所有GH缺乏症（GHD）受试者的标准治疗，但传统上不给予GH的肢端肥大症亚组除外。GHD综合征表现为心血管风险增加，这可能通过GH治疗逆转。心血管疾病是肢端肥大症的主要死因。虽然肢端肥大症的治愈与GH过量导致的死亡率降低有关，但GHD可能是该组患者心血管发病率和死亡率的一个促成因素，就像其他垂体瘤患者一样。 本研究的目的是评估生理性生长激素（GH）替代治疗对肢端肥大症治疗后GH缺乏的男性和女性的心血管风险标志物、心脏自主神经功能、动脉扩张性、身体成分和生活质量的影响。我们将在一项横断面研究中比较GH充足与GH缺乏治愈的肢端肥大症。我们假设，这一人群将代表一个新确定的一组患者的GH替代将受益。